Mostafa Taymour
Andrology & Sexology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
J Sex Med. 2008 Nov;5(11):2502-18. doi: 10.1111/j.1743-6109.2008.00983.x. Epub 2008 Aug 26.
Phosphodiesterase type 5 (PDE5) hydrolyses cyclic guanylate monophosphate (cGMP) specifically to 5' GMP. PDE5 inhibitors were a breakthrough medication that addressed a previously unfulfilled medical need. They promoted vascular relaxation in the corpora cavernosa and penile erection during sexual stimulation. Sildenafil, vardenafil, and tadalafil were approved then introduced as effective treatments for male erectile dysfunction. This impact has stimulated academic, clinical, and industrial research.
To highlight the nonerectogenic beneficial uses of oral PDE5 inhibitors.
A systematic review of published studies in this affair based on a Pubmed and medical subject heading databases search of all concerned articles.
Demonstrated beneficial as well as applicable uses of oral PDE5 inhibitors.
As chemical molecules, these drugs were shown to exert potential nonerectogenic beneficial effects. They showed efficacy as a useful adjunct in the management of pulmonary hypertension. Additional uses were extended to different utilities: essential hypertension, benign prostatic hyperplasia, gastrointestinal disorders, endothelial dysfunction, female sexual dysfunction, genital blood flow, exercise capacity, Raynaud's phenomenon, sperm motility, etc.
Exploring PDE5 inhibitors for their possible medical applications in diverse specialties seems to be beneficial in making use of these molecules for the welfare of humanity.
5型磷酸二酯酶（PDE5）特异性地将环磷酸鸟苷（cGMP）水解为5'-鸟苷单磷酸（5'GMP）。PDE5抑制剂是一种突破性药物，满足了此前未被满足的医疗需求。它们可促进性刺激期间海绵体的血管舒张及阴茎勃起。昔多芬、伐地那非和他达拉非随后获批并作为男性勃起功能障碍的有效治疗药物被引入。这一影响激发了学术、临床和产业研究。
强调口服PDE5抑制剂的非勃起相关有益用途。
基于对PubMed及医学主题词数据库中所有相关文章的检索，对该领域已发表的研究进行系统综述。
口服PDE5抑制剂已证实的有益及适用用途。
作为化学分子，这些药物显示出潜在的非勃起相关有益作用。它们在肺动脉高压的治疗中作为有用的辅助药物显示出疗效。其他用途还扩展到不同领域：原发性高血压、良性前列腺增生、胃肠道疾病、内皮功能障碍、女性性功能障碍、生殖器血流、运动能力、雷诺现象、精子活力等。
探索PDE5抑制剂在不同专业领域可能的医学应用，似乎有利于利用这些分子造福人类。
